| Customization: | Available |
|---|---|
| Powder: | Yes |
| Customized: | Ready to Ship |
|
Still deciding? Get samples of US$ 1/g
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
Lapatinib ditosylate powder cas 388082-77-7
Breast cancer remains a leading cause of disease and death among women throughout the world. Despite advances in drug therapy, development of novel and improved drugs for breast cancer continues to be of great interest. Lapatinib is a novel dual receptor tyrosine kinase inhibitor that is a selective and potent inhibitor of ErbB-1 and ErbB-2 tyrosine kinases, both of which are growth promoting factors overexpressed in some breast cancers.
Why choose us?
After more than ten years of development, the company has established close cooperative relations with many domestic chemical research institutions and has a number of production bases. Production in strict accordance with ISO, GMP,FDA standards, products through strict factory testing, to ensure 100% qualified products.
){kind=link}